Table 1.
Baseline clinical characteristics of the patients.
| Characteristics | All patients (n = 30) |
|---|---|
| Age, yr | 73.00 (66.75–76.00) |
| Male | 26 (86.7) |
| Weight | 65.50 (59.75–73.00) |
| Height | 163.00 (156.75–167.00) |
| Body mass index | 24.69 (23.38–27.34) |
| Never smoker | 4 (13.3) |
| Ever-smokers | 26 (86.7) |
| Pack-years | 36.50 (19.63–47.75) |
| GAP stage | 1.00 (1.00–2.00) |
| Use of antifibrotic agent | 29 (96.7) |
| Dose of PFD, mg/day | 1200 (600–1800) |
| Duration of PFD | 452.00 (279.50–561.00) |
| Dyspnea, mMRC | 1.00 (1.00–2.00) |
| Pulmonary function test | |
| FVC, % predicted | 77.50 (67.75–92.50) |
| FEV1, % predicted | 85.00 (70.75–97.50) |
| DLco, % predicted | 62.00 (50.00–71.00) |
| Six-minute walk test | |
| Distance (m) | 454.50 (354.75–508.50) |
| Initial SpO2 (%) | 96.00 (95.00–97.75) |
| Nadir SpO2 (%) | 92.50 (89.00–94.00) |
| Arterial oxygen pressure | 87.86 (69.70–100.38) |
| PaCO2 (mm Hg) | 37.90 (35.15–8.17) |
| WBC | 7.40 (6.26–8.17) |
| IL-6 | 5.60 (4.20–9.50) |
| CRP | 0.24 (0.14–0.53) |
Data are presented as median (interquartile range) or number (%), unless otherwise indicated.
CRP = C-reactive protein, DLco = diffusing capacity of the lungs for carbon monoxide, FEV1 = forced expiratory volume in 1 second, FVC = forced vital capacity, GAP = gender-age-pulmonary function, IL-6 = interleukin-6, mMRC = modified medical research council, PaCO2 = partial pressure of carbon dioxide, PFD = pirfenidone, SpO2 = saturation of percutaneous oxygen, WBC = white blood cell.